Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Dr. Iwao Ojima

TB R&D Update: Podcast Interview with Dr. Iwao Ojima

Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compou...

Listing to Podcast

View All Podcasts »

exposed

UPDATE Exposed: Aeras’ Film Series on Tuberculosis

Release of Chapter 1 of EXPOSED occured the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals - an MDR...

Watch Video

View All Videos »

MSF video

Multidrug-Resistance Tuberculosis: No Promises

A video from Medecins Sans Frontieres entitled "Multidrug-Resistance Tuberculosis: No Promises" on the situation of children affected with MDR-TB. It highlights the dire plight of children being treated for MDR-TB in Tajikistan....

Watch Video

View All Videos »

thumb206-andy

The Growing Landscape of TB Trials: Interview with Dr. Andrew Vernon

This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug developmen...

Watch Video

View All Videos »

previous next

Messages to our members

WGND Annual Meeting, Oct. 29th

This meeting will be  held before the 45th Union World Conference on Lung Health on October 29th, from 15:00 to 19:00. Register by sending an email to Private Email.

View All Messages »

From the blog

Moxifloxacin

Results of Phase III ReMoxTB Clinical Trial Published

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]

Posted 9 September 2014 | No Comments

Get involved

Site features

Global Discovery Programs

An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.

View Pipeline

The Global TB Drugs Pipeline

An online tool that invites developers to submit their TB drug candidates so we can provide a more complete snapshot of current global efforts.

View Pipeline

TB Resources Database

A growing collection of resources to help access Tools, Knowledge, Facilities, and People in the TB drug development R&D community.

View TB Resources

Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.

Read More

About us

Our Mission

To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.
Read More »

Global Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.
Read More »

Total members: 250

WGND Members:

Belen Barrio

Sanofi-Aventis R&D

Anne Lenaerts

Colorado State University

Christo van Niekerk

TB Alliance

Boitumelo Semete

Council of Scientific Industrial Research (CSIR) in South Africa

Peter Small

Bill & Melinda Gates Foundation

David Greeley

TB Alliance

Zahoor Ahmed

National T.B Control Programme

Valerie Mizrahi

UCT-Institute of Infectious Disease and Molecular Medicine

Federico Gómez de las Heras

GlaxoSmithKline

Brian Robertson

Imperial College London

View All Members »